Cyclin D1 in breast premalignancy and early breast cancer: Implications for prevention and treatment

Cancer Letters

Volumn 162, Issue 1, 2001, Pages 3-17

  Zhou, Qun ^a   Hopp, Torsten ^b   Fuqua, Suzanne A W ^b   Steeg, Patricia S ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Apo 2; Apoptosis; Atypical ductal hyperplasia; Breast cancer; Cell cycle; Cyclin D; Ductal carcinoma in situ; Estrogen receptor; Radiation; Tumorigenesis

Indexed keywords

CYCLIN D1; ESTROGEN; ESTROGEN RECEPTOR;

APOPTOSIS; BREAST BIOPSY; BREAST CANCER; CANCER PREVENTION; CARCINOGENESIS; CARCINOMA IN SITU; CELL CYCLE; CELL CYCLE G1 PHASE; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION INJURY; SHORT SURVEY; TRANSACTIVATION; TRANSCRIPTION INITIATION;

EID: 0035834872     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(00)00657-1     Document Type: Review

References (96)

1. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
2. The effect of raloxifene on risk of breast cancer in postmenopausal women
3. Cylcin D1 in breast cancer
4. Cyclins and breast cancer
5. Cyclins, cyclin-dependent kinases and differentiation
6. Cancer cell cycles
7. Control of the G1/S transition
8. Cyclins and cancer II: Cyclin D and cdk inhibitors come of age
9. Risk factors for breast cancer in women with proliferative breast disease
10. Ductal carcinoma in situ of the breast
11. Mortality among women with ductal carcinoma in situ of the breast in the population based suveillance, epidemiology and end results program
12. Radial scars in benign breast-biopsy specimens and the risk of breast cancer
13. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia
14. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types
15. Atypical hyperplasias of the female breast. A long term follow-up study
16. Anatomic markers of human premalignancy and risk of breast cancer
17. A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast
18. A prospective study of benign breast disease and the risk of breast cancer
19. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci
20. LOH analyses of premalignant and malignant lesions of human breast: Frequent LOH in 8p, 16q and 17q in atypical ductal hyperplasia
21. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: Implications for tumorigenesis
22. Comparative genomic hybridization of ductal carcinoma in situ of the breast - Evidence of multiple gentic pathways
23. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17
24. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer
25. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial
26. Predictors of local recurrence after treatment of ductal carcinoma in situ
27. The influence of margin width on local control of ductal carcinoma in situ of the breast
28. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions
29. Cyclin D-1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast
30. Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast
31. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast
32. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia
33. Immunohistochemical evaluation of c-erb-B-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast
34. Distinct angiogeneic patterns are associated with high-grade in situ ductal carcinomas of the breast
35. Ductal carcinoma in situ of the breast: Frequency of biomarkers according to histologic subtype
36. Microvessel density and distribution in ductal carcinoma in situ of the breast
37. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer
38. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast
39. p21 (WAF1) immunohistochemical expression in breast carcinoma: Correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival
40. Neu-protein overexpression in breast cancer
41. p53 protein expression in mammary ductal carcinoma in situ: Relationship to immunohistochemical expression of estrogen receptor and c-erb-B-2 protein
42. p53 mutations are confined to the comdeo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data
43. Molecular and immunohistochemical analysis of p53 mutations in scrapings and tissue from preinvasive and invasive breast cancer
44. Expression of p53 protein in benign epithelial hyperplasia, atypical ductal hyperplasia, non-invasive and invasive mammary carcinoma: An immunohistochemical study
45. Evidence of significant apoptosis in poorly differentiated ductal carcinoma in situ of the breast
46. Nm23 product expression in in situ and invasive human breast cancer
47. Cell cycle inhibitors: Three families united by a common cause
48. Rb function in cell-cycle regulation and apoptosis
49. The p21cip1 and p27kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts
50. p21 WAF/CIP1 mutants deficient in inhibiting cyclin-dependent kinases (CDKs) can promote assembly of active cyclin D/CDK4(6) complexes in human tumor cells
51. The hallmarks of cancer
52. Physical interaction of the retinoblastoma protein with human D cyclins
53. Proliferating cell nuclear antigen and p21 are components of multiple cell-cycle kinase complexes
54. Tumorigenicity and gene amplification potentials of cyclin D1-overexpressing NIH3T3 cells
55. Overexpression of cyclin D1 enhances gene amplification
56. Gene expression and cell cycle arrest mediated by transcription factor DMP1 is antagonized by D-type cyclins though a cyclin-denpendent-kinase-independent mechanism
57. Cyclin D1 associates with the TBP-associated factor TAF(II)250 to regulate Sp1-mediated transcription
58. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
59. Stable overexpression of cyclin D1 in a human mammary epithelial cell line prolongs the S-phase and inhibits growth
60. Increased expression of cyclin D1 in a murine mammary epithelial cell line induces p27kip1, inhibits growth and enhances apoptosis
61. Constitutive expression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor
62. Cyclin D1 overexpression in a model of human breast premalignancy: Preferential stimulation of anchorage-independent, but not anchorage-dependent growth is associated with increased cdk2 activity
63. Functional consequences of cyclin D1 overexpression in human mammary luminal epithelial cells
64. CDK-independent activation of estrogen receptor by cyclin D1
65. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4
66. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1
67. PCAF associates with cyclin D1 and potentiates its activation of the estrogen receptor
68. Characterization of the estrogen receptor transfected MCF10A breast cell line 139B6
69. Cyclin D1 induced apoptosis maintains the integrity of the G1/S checkpoint following ionizing radiation irradiation
70. Cyclin D1 is an essential mediator of apoptotic neuronal cell death
71. Analysis of cell cycle-related gene expression in postmitotic neurons: Selective induction of cyclin D1 during programmed cell death
72. Radiation and the Apo2L/TRAIL apoptotic pathway preferentially inhibit the colonization of premalignant human breast cells overexpressing cyclin D1
73. Treatment of early stage breast cancer
74. Identification and characterization of a new member of the TNF family that induces apoptosis
75. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
76. Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation
77. Is there a role for molecular prognostic factors in the clinical management of ductal carcinoma in situ (DCIS) of the breast?
78. Balance of cell proliferation and apoptosis in breast carcinogenesis
79. Characterization of the cylin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule
80. Apoptosis induced in mammalian cells by small peptides that functionally antagonize the RB-regulated E2F transcription factor
81. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo
82. Preclinical and clinical development of cyclin-dependent kinase modulators
83. Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro
84. Retinoids in cancer chemoprevention
85. Role of retinoid receptors in the prevention and treatment of breast cancer
86. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
87. 4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RAR gamma independent pathway
88. Inhibition of cancer cell growth by all-trans retinoic acid and its analog N-(4-hydroxyphenyl) retinamide: A possible mechanism of action via regulation of retinoid receptors expression
89. Progressive decrease in nucelar retinoic acid beta mesenger RNA level during breast carcinogenesis
90. A high risk lesion for invasive breast cancer, ductal carcinoma in situ, exhibits frequent overexpression of retinoid X receptor
91. Retinoic acid receptors alpha, beta, gamma, and cellular retinol binding protein-I expression in breast fibrocystic disease and cancer
92. Prevention of breast cancer in the rat with 9-cis-retinoic acid as single agent and in combination with tamoxifen
93. Pilot trial of the safety, tolerability and retinoid levels of N(4-hydroxyphenyl) reinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer
94. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis inducing ligand
95. Chemoprevention: General perspective
96. Cancer chemoprevention: Progress and promise